LONDON – Spring has arrived on cue for European biotech with the launch of a new €150 million (US$199 million) venture capital fund from Index Ventures – with backing and active involvement from two pharma partners, GlaxoSmithKline plc and Johnson & Johnson – to specialize in investing in early stage companies.